Browsing Tag
Yesafili
4 posts
Biocon Biologics (NSE: BIOCON) clears global aflibercept deal with Regeneron, Bayer for Yesafili rollout
Biocon Biologics secures global aflibercept launch rights for Yesafili after Regeneron–Bayer settlement. Find out what this means for biosimilar strategy.
How Canada became the preferred launchpad for ophthalmic biosimilars in 2025
With Yesafili’s approval, Canada is emerging as the global launchpad for ophthalmic biosimilars. Explore what’s driving this strategic shift.
Biocon Biologics gets Health Canada approval for Yesafili aflibercept biosimilar
Biocon Biologics wins Health Canada approval for Yesafili, its 10th biosimilar. Find out how this launch could reshape retinal care access in Canada.
Can Biocon Biologics lead biosimilar disruption in ophthalmology with Yesafili?
Biocon Biologics secures 2026 U.S. launch for Yesafili, its interchangeable biosimilar to Eylea. Find out how this reshapes eye care access and competition.